The global ovarian cancer diagnostics market is experiencing significant growth due to the increasing prevalence of ovarian cancer, rising awareness about early detection, and advancements in diagnostic technologies. The demand for effective screening methods is driven by the high mortality rate associated with late-stage diagnosis, emphasizing the need for early and accurate detection. Innovations in biomarker-based tests, liquid biopsies, and next-generation sequencing (NGS) are improving diagnostic accuracy and efficiency. In addition, government initiatives and research funding aimed at enhancing cancer diagnostics are further fueling market expansion. However, challenges such as the high cost of advanced diagnostic procedures, limited accessibility in developing regions, and the complexity of early-stage detection may hinder market growth.
Global Ovarian Cancer Diagnostics Market is expected to reach USD 11.64 billion by 2030, with a growing CAGR of 7.0% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-ovarian-cancer-diagnostics-market
Below are the Top Ovarian Cancer Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
Roche is a global leader in diagnostics and pharmaceuticals, offering advanced molecular and immunohistochemistry (IHC) tests for ovarian cancer detection. Its cobas and VENTANA platforms provide high-precision diagnostics, enabling early detection and personalized treatment. Roche’s focus on biomarker-based testing, including CA-125 and HE4 assays, strengthens its position in ovarian cancer diagnostics.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2022, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
|
|
2.
|
Tosoh India Pvt. Ltd.
|
Tosoh India Pvt. Ltd., a subsidiary of Tosoh Corporation (Japan), specializes in diagnostic and laboratory solutions, including automated immunoassay analyzers for ovarian cancer detection. The company’s AIA-Series analyzers provide high-speed and accurate detection of ovarian cancer markers such as CA-125. Tosoh is known for its reliable and high-throughput diagnostic solutions for cancer screening.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In April 2015, Tosoh Corporation acquired Mumbai-based clinical diagnostic products company Lilac Medicare Pvt Ltd to establish bio-science operations in India. This acquisition is part of Tosoh’s strategy to expand and strengthen its bioscience operations.
|
|
3.
|
Luminex Corporation
|
Luminex Corporation, now part of DiaSorin, is a biotechnology company specializing in multiplexed diagnostic solutions for ovarian cancer. Its xMAP® and xTAG® technology allows for high-throughput detection of multiple ovarian cancer biomarkers in a single test. Luminex’s assays enhance early diagnosis and risk stratification, contributing to precision medicine in ovarian cancer management.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2008, Luminex Corp and BD announced the signing of a development and supply agreement to develop, market, and sell new biomarker-based diagnostic tests for certain cancers such as ovarian and breast cancer, using Luminex’s multiplexing xMAP Technology platform.
|
|
4.
|
Quest Diagnostics Incorporated
|
Quest Diagnostics is a leading provider of clinical laboratory services, offering comprehensive ovarian cancer screening and biomarker testing. The company provides CA-125 and HE4 tests, along with advanced genetic testing for hereditary ovarian cancer risks, such as BRCA1 and BRCA2 mutations. Quest’s nationwide network ensures widespread accessibility to ovarian cancer diagnostics.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In October 2022, Quest Diagnostics announced the new phase of collaboration with Decode health, in the starting phase of collaboration, the two parties developed RNA (transcriptome) sequencing capabilities based on both parties' next-generation sequencing, analytics, and clinical expertise. The collaboration is significant as biomarker-based data can help reduce the time and cost of developing novel diagnostic tests and identifying new drug targets for different types of cancers (breast, prostate, and ovarian cancer).
|
|
5.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific is a global leader in molecular and protein-based diagnostics for ovarian cancer detection. The company offers ELISA kits, PCR-based assays, and biomarker tests for early detection and disease monitoring. Its high-sensitivity detection platforms help identify ovarian cancer at an early stage, supporting personalized treatment strategies.
|
OVTL16
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2022, Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Glacios 2 Cryo-Transmission Electron Microscope (Cryo-TEM), a powerful microscope with new automation and high-resolution imaging capabilities designed to help cryo-Electron Microscopy (cryo-EM) researchers of varying experience levels accelerate structure-based drug discovery.
|
Conclusion
The global ovarian cancer diagnostics market is expected to witness steady growth as technological advancements and increasing awareness drive demand for early detection solutions. The integration of AI-driven diagnostics, precision medicine, and biomarker research will further enhance diagnostic accuracy, improving patient outcomes. While challenges such as cost constraints and accessibility remain, ongoing research, government initiatives, and investments in early-stage detection methods will continue to support market expansion.
